Technical Analysis for AKRO - Akero Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
C | 45.36 | -1.22% | -0.56 |
AKRO closed down 1.22 percent on Monday, September 25, 2023, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Oct 1
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 200 DMA | Bearish | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Doji - Bullish? | Reversal | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Possible NR7 | about 6 hours ago |
60 Minute Opening Range Breakdown | about 9 hours ago |
Down 2 % | about 9 hours ago |
200 DMA Support | about 10 hours ago |
200 DMA Resistance | about 10 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 10/01/2023
Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Alcohol Clinical Trial Steatohepatitis Hepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Alcohol Clinical Trial Steatohepatitis Hepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 58.38 |
52 Week Low | 26.37 |
Average Volume | 706,695 |
200-Day Moving Average | 45.65 |
50-Day Moving Average | 46.76 |
20-Day Moving Average | 49.60 |
10-Day Moving Average | 49.52 |
Average True Range | 1.94 |
RSI (14) | 35.90 |
ADX | 26.47 |
+DI | 22.63 |
-DI | 27.16 |
Chandelier Exit (Long, 3 ATRs) | 47.94 |
Chandelier Exit (Short, 3 ATRs) | 50.82 |
Upper Bollinger Bands | 52.91 |
Lower Bollinger Band | 46.29 |
Percent B (%b) | -0.14 |
BandWidth | 13.35 |
MACD Line | 0.13 |
MACD Signal Line | 0.82 |
MACD Histogram | -0.6889 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 46.79 | ||||
Resistance 3 (R3) | 46.82 | 46.38 | 46.55 | ||
Resistance 2 (R2) | 46.38 | 46.02 | 46.36 | 46.47 | |
Resistance 1 (R1) | 45.87 | 45.79 | 45.65 | 45.84 | 46.39 |
Pivot Point | 45.43 | 45.43 | 45.32 | 45.41 | 45.43 |
Support 1 (S1) | 44.92 | 45.07 | 44.70 | 44.89 | 44.33 |
Support 2 (S2) | 44.48 | 44.84 | 44.46 | 44.25 | |
Support 3 (S3) | 43.97 | 44.48 | 44.17 | ||
Support 4 (S4) | 43.94 |